^
    Back
    Association details:
    Biomarker:AURKB overexpression
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Theranostics
    Title:

    HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E

    Published date:
    08/01/2020
    Excerpt:
    Notably, AURKB is expressed markedly higher in vemurafenib-resistant (A375R, M238R, and M249R) compared with vemurafenib-sensitive melanoma cell lines (A375, M238, and M249; Figure ​Figure11H). All these results demonstrate that AURKB could be a potential target for melanoma treatment and in overcoming drug resistance.
    DOI:
    10.7150/thno.44342